Cost of treating HIV remains high; Louisiana feels the pain
- Non-Adherence to Anti-Tuberculosis Treatment and Determinant Factors among Patients with Tuberculosis in Northwest Ethiopia. Adane, Akilew Awoke; Alene, Kefyalew Addis; Koye, Digsu Negese; Zeleke, Berihun Megabiaw // PLoS ONE;Nov2013, Vol. 8 Issue 11, p1
Background: Non-adherence to anti tuberculosis treatment is one of the crucial challenges in improving tuberculosis cure-rates and reducing further healthcare costs. The poor adherence to anti-tuberculosis treatment among patients with tuberculosis is a major problem in Ethiopia. Hence, this...
- Modelling the Potential Economic Impact of Viral Load-Driven Triple Drug Combination Antiretroviral Therapy. Anis, A.H.; Hogg, R.S.; Wang, X-h.; Yip, B.; Palepu, A.; Montaner, J.S.G.; O’Shaughnessy, M.V.; Schechter, M.T. // PharmacoEconomics;1998, Vol. 13 Issue 6, p697
The purpose of this study is to model the potential economic impact of viral load-driven triple drug combination (including a protease inhibitor) antiretroviral therapy on incremental drug and hospitalisation costs among individuals with HIV disease. Individuals included in the study were...
- Financing Health Care for Persons with HIV Infection: Guidelines for State Action. Fox, Daniel M. // American Journal of Law & Medicine;1990, Vol. 16 Issue 1/2, p223
Promises of confidentiality of HIV-related medical records and protection from discrimination based on HIV seropositivity are two of the legislative inducements state governments have offered to encourage voluntary HIV testing. Yet neither can be granted without impact on others whose interests...
- Pentafuside effective. // AIDS Patient Care & STDs;Apr96, Vol. 10 Issue 2, p130
Reports on the effectiveness of pentafuside in preventing infection by HIV-1 in mice. Overview of the study on pentafuside performed in collaboration with US Food & Drug Administration; Mechanism of action.
- Pentafuside shows anti-HIV activity. // AIDS Patient Care & STDs;Jun96, Vol. 10 Issue 3, p184
Relates the results of a study conducted on the effect of pentafuside on HIV-infections in mice. Systemic effect of the drug; Ability of the drug to reduce the extent of HIV infection.
- Resistance, remission, and qualitative differences in HIV chemotherapy. Kirschner, Denise E.; Webb, G.F. // Emerging Infectious Diseases;Jul-Sep97, Vol. 3 Issue 3, p273
Presents a design of a mathematical system that models human immunodeficiency virus (HIV) multidrug chemotherapy including uninfected and infected CD4+T cells and virus population. Inclusions in the model; Indications from the simulations; Important distinction between resistance and remission;...
- First of a new class of drugs for HIV. // Modern Medicine;Feb96, Vol. 64 Issue 2, p38
Reports on the United States Food and Drug Administration's approval of the drug Saquinavir mesylate (Invirase), indicated for HIV infections. Mode of action.
- First-line treatment of HIV infection. // Modern Medicine;Nov96, Vol. 64 Issue 11, p33
Reports on the Food and Drug Administration's approval of Didanosine as a monotherapy for treating HIV infection when antiretroviral therapy is warranted.
- Prescriptions pile up for AIDS combination therapy. Rodgers, Katie // Drug Topics;1/8/96, Vol. 140 Issue 1, p14
Reports on developments related to chemotherapy for advanced HIV infection. Includes the US Food & Drug Administration's approval of saquinavir protease inhibitor; Combination therapy with nucleoside analogs; Prescriptions for lamivudine.